provided additional evidence to suggest that downregulation of ZEB1 is essential for the LMO2 driven stemness phenotype in T-ALL cells as well as resistance to methotrexate treatment, a chemotherapeutic drug used to treat T-ALL (165). This evidence concerns the gene LMO2 and acute lymphoblastic leukemia.